Fischer Medical Ventures MD, chairman, board of directors and AGM
NSE: FISCHERBSE: 524743Healthcare Equipment & SuppliesSmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹23.87.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹1,738 Cr1,073rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 14 Aug 2026
- 58.1
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.20%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 14 Aug 2026
- 8.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 14 Aug 2026
- 10.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 31 May 2026
- 0.19
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 91,74,21521.6% delivered
Fischer Medical Ventures board of directors
At the end of the quarter to Jun 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
- Chairperson and managing directorRAVINDRAN GOVINDAN
- Company Secretary and Compliance OfficerBalaji Gandla
8 directors6 independent2 executive
- RAVINDRAN GOVINDAN · Chairperson and managing directorExecutive · joined May 2024 · 25 months as independent · 1 listed board · 2 committee seats
- SVETLANA RAO RAVIWADAExecutive · joined May 2024 · 25 months as independent · 1 listed board · 1 committee seat
- KHAIRY JAMALUDDIN ABU BAKARIndependent · joined May 2024 · 25 months as independent · 1 listed board · 1 as independent · 1 committee seat, 1 as chair
- SANJAY JAYANTILAL JAINIndependent · joined Oct 2021 · 56 months as independent · 1 listed board · 1 as independent · 1 committee seat
- ROBERTO M PADGDANGANANIndependent · joined Jul 2024 · 23 months as independent · 1 listed board · 1 as independent · 1 committee seat
- JAYA ANKUR SINGHANIAIndependent · joined Mar 2025 · 15 months as independent · 4 listed boards · 4 as independent · 8 committee seats, 2 as chair
- CHAN SING ENIndependent · joined Oct 2025 · 8 months as independent · 1 listed board · 1 as independent · 1 committee seat
- SYED JALALUDINIndependent · joined Nov 2025 · 7 months as independent · 1 listed board · 1 as independent · 1 committee seat
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
1 director who left
- DR. JACOB THOMAS, left 14 Aug 2025: Others
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 29 May 20266 of 8 present4 independent · 65 days in between
- 24 Mar 20268 of 8 present6 independent
- 30 Jan 20267 of 8 present5 independent
Audit Committee
Chair KHAIRY JAMALUDDIN ABU BAKAR
SANJAY JAYANTILAL JAIN, RAVINDRAN GOVINDAN, JAYA ANKUR SINGHANIA, ROBERTO M PADGDANGANAN, CHAN SING EN, SYED JALALUDIN
- 28 May 20265 of 7 present4 independent · 61 days in between
- 27 Mar 20266 of 7 present6 independent · 56 days in between
- 29 Jan 20266 of 7 present5 independent
Nomination and remuneration committee
Chair KHAIRY JAMALUDDIN ABU BAKAR
ROBERTO M PADGDANGANAN, JAYA ANKUR SINGHANIA, RAVINDRAN GOVINDAN, SYED JALALUDIN
- 24 Mar 20265 of 5 present4 independent
Stakeholders Relationship Committee
Chair JAYA ANKUR SINGHANIA
SVETLANA RAO RAVIWADA, RAVINDRAN GOVINDAN
No meeting listed in the filing.
Risk Management Committee
Chair SVETLANA RAO RAVIWADA
RAVINDRAN GOVINDAN, KHAIRY JAMALUDDIN ABU BAKAR, JAYA ANKUR SINGHANIA, CHAN SING EN
- 29 Jan 20264 of 5 present2 independent
Corporate Social Responsibility Committee
Chair SVETLANA RAO RAVIWADA
ROBERTO M PADGDANGANAN, JAYA ANKUR SINGHANIA, RAVINDRAN GOVINDAN, CHAN SING EN
No meeting listed in the filing.
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Jun 2026.
- Bilimoria Mehta & CoPeer-review certificate valid to Jun 2027
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Fischer Medical Ventures AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Fischer Medical Ventures dividend history
Annual general meeting, 29 Sep 2026
25,728 shareholders on the register on 22 Sep 2026; present: 2 promoters and 59 others; votes counted by Nuren Lodaya / Nuren Lodaya and Associates.The company's voting result (opens in a new tab)
To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended 31st March, 2026 together with the Reports of the Board of Directors and the Auditors thereon.MoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 66.40% · promoters 92.29% · institutions 0.02% · other public 27.83%
- To declare a dividend of 5% per Equity Share on the face value for the financial year ended 31st March 2026.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 66.40% · promoters 92.29% · institutions 0.02% · other public 27.83%
- To appoint a Director in place of Ms. Svetlana Rao Raviwada (DIN: 06899295), who retires by rotation and being eligible, offers herself for re-appointment.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 66.40% · promoters 92.29% · institutions 0.02% · other public 27.83%
- To appoint Mr. David Yeow (DIN: 11923054) as Independent Director for a term of five yearsSpecial100.00% for0.00% against
Against: promoters 0.00% · institutions 29.53% · other public 0.00%
Turnout: all 66.40% · promoters 92.29% · institutions 0.02% · other public 27.83%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Postal ballot, 30 Nov 2025, 2 resolutions
13,284 shareholders on the register on 24 Oct 2025; votes counted by Nuren Lodaya / M/s Nuren Lodaya and Associated.The company's voting result (opens in a new tab)
- Appointment of Mr. Chan Sing En as Independent Director of the CompanySpecial100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.02%
Turnout: all 62.49% · promoters 100.00% · institutions 0.01% · other public 2.23%
- Appointment of Dr. Syed Jalaludin as the Independent DirectorSpecial100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.07%
Turnout: all 62.49% · promoters 100.00% · institutions 0.01% · other public 2.23%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Annual general meeting, 29 Sep 2025, 5 resolutions
13,199 shareholders on the register on 22 Sep 2025; present: 2 promoters and 65 others; votes counted by NUREN LODAYA / NUREN LODAYA AND ASSOCIATES.The company's voting result (opens in a new tab)
To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended 31st March, 2025 together with the Reports of the Board of Directors and the Auditors thereon.MoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 71.51% · promoters 100.00% · institutions 0.00% · other public 31.10%
- To declare a dividend of 0.5% per Equity Share on the face value for the financial year ended 31st March 2025.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 71.51% · promoters 100.00% · institutions 0.01% · other public 31.10%
- To appoint a Director in place of Mr. Ravindran Govindan (DIN: 03137661), who retires by rotation and being eligible, offers himself for re-appointment.OrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 20.35% · promoters 17.22% · institutions 0.01% · other public 31.10%
To consider and if thought fit, to pass, the following Resolution as an Ordinary Resolution for re-appointment of M/s Bilimoria Mehta & Co. Chartered Accountants as the Statutory Auditors of the CompanyMoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 71.51% · promoters 100.00% · institutions 0.01% · other public 31.10%
- Appointment of Secretarial AuditorOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 71.51% · promoters 100.00% · institutions 0.01% · other public 31.10%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Postal ballot, 30 Aug 2025, 2 resolutions
10,513 shareholders on the register on 25 Jul 2025; votes counted by NUREN LODAYA / NUREN LODAYA AND ASSOCIATES.The company's voting result (opens in a new tab)
- To consider and approve the sub-division / split of existing Equity Shares of the Company pursuant to the provisions of Section 61 of the Companies Act, 2013.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 7.97% · promoters 100.00% · institutions 89.90% · other public 1.26%
- To approve amendments in the Capital clause of the Memorandum of Association of the companyOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 7.97% · promoters 100.00% · institutions 89.90% · other public 1.26%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
How mutual funds voted
Fund houses must disclose how they vote at every meeting of a company they hold.
Mutual fund votes, meeting of 30 Nov 2025, 2 fund houses
- Appointment of Mr. Chan Sing En as Independent Director of the Company2 for0 against
- Appointment of Dr. Syed Jalaludin as the Independent Director2 for0 against
Mutual fund votes, meeting of 29 Sep 2025, 2 fund houses
To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended 31st March, 2025 together with the Reports of the Board of Directors and the Auditors thereon.MoreLess
2 for0 against- To declare a dividend of 0.5% per Equity Share on the face value for the financial year ended 31st March 2025.2 for0 against
- To appoint a Director in place of Mr. Ravindran Govindan (DIN: 03137661), who retires by rotation and being eligible, offers himself for re-appointment.2 for0 against
To consider and if thought fit, to pass, the following Resolution as an Ordinary Resolution for re-appointment of M/s Bilimoria Mehta & Co. Chartered Accountants as the Statutory Auditors of the CompanyMoreLess
2 for0 against- Appointment of Secretarial Auditor2 for0 against
Each fund house counted once, from its own disclosure; the reasons are its own words.
Stakes in unlisted companies
Reported in the filing for the quarter to Jun 2026.
- Unlisted stake heldTime Medical International Ventures India Private LimitedSince 25 Jan 2024
0.00% bought in the quarter; holding 100.00%, from 100.00%
- Unlisted stake heldFlynnCare Health Innovations Private LimitedSince 29 Jul 2024
0.00% bought in the quarter; holding 100.00%, from 100.00%
- Unlisted stake heldWonderTech Medical Solutions Private LimitedSince 13 Nov 2024
0.00% bought in the quarter; holding 51.00%, from 51.00%
- Unlisted stake heldNanyang Biologics India Private LimitedSince 14 Feb 2025
0.00% bought in the quarter; holding 51.00%, from 51.00%
- Unlisted stake heldFischer Hospitality Sdn BhdSince 15 May 2025
0.00% bought in the quarter; holding 60.00%, from 60.00%
- Unlisted stake heldObelabs IncSince 3 May 2025
0.00% bought in the quarter; holding 1.60%, from 1.60%
- Unlisted stake heldFMV Healthcare PTE LtdSince 26 Aug 2024
0.00% bought in the quarter; holding 100.00%, from 100.00%
- Unlisted stake heldFMV Global Innovations PTE LtdSince 15 Oct 2025
0.00% bought in the quarter; holding 100.00%, from 100.00%
1 more
- Unlisted stake heldFMV International Ventures PTE LtdSince 26 Aug 2024
0.00% bought in the quarter; holding 100.00%, from 100.00%
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- Yes
- The chair is related to the managing director
- Yes
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Mar 2026. The company's results filing for the quarter to Jun 2026 says no statement of how money raised was used applies to it. A preferential issue sells new shares to chosen investors rather than to the public. A warrant or partly paid issue plans the whole issue while the money comes in over time, so the amount set aside can be more than raised so far. A statement's amounts are left out where the raise it states is more than ten times everything the company owns, a figure typed at the wrong scale.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere |
|---|---|---|---|---|---|
| Preferential IssuesMar 2026, checked by Infomerics Valuation and Rating Limited | – | – | – | No |